<div id="readability-page-1"><div><p>By Colin Kellaher</p><p>   Shares of Protagonist Therapeutics moved higher after The Wall Street Journal reported that Johnson &amp; Johnson is in talks to buy company, citing people familiar with the matter. </p><p>    Protagonist shares were recently up 9.4%, to $73.34. </p><p>    A deal isn't guaranteed, and the details being discussed couldn't be learned, the people said, the Journal reported. </p><p>    Protagonist sports a market capitalization topping $4 billion based on Thursday's closing price of $67.04 for the Newark, Calif., clinical-stage biopharmaceutical company. </p><p>   Write to Colin Kellaher at colin.kellaher@wsj.com </p><p>   (END) Dow Jones Newswires</p><p>10-10-25 1147ET</p></div></div>

PTGX

<p>Shares of Protagonist Therapeutics rose 9.4% to $73.34 following a report from The Wall Street Journal that Johnson & Johnson is in talks to acquire the company. Protagonist has a market capitalization exceeding $4 billion based on its recent closing price of $67.04. However, the deal is not guaranteed, and specific details remain undisclosed.</p>

Protagonist Therapeutics Leaps on Report of Possible J&J Deal